Potential disconnect: Objective Inflammatory Response, OIR (MRI/CRP levels) vs Clinical Response,CR (BASDAI/ASDAS). Post hoc analysis AxSpA on Certolizumab. Majority of patients >50% improved OIR, only minority improved CR. Rudwaleit etal t.co/WdkmkCWClO #ACR22 @RheumNow
An Exploratory Analysis of the Potential Disconnect Between Objective Inflammatory Response and Clinical Response Following Certolizumab Pegol Treatment in Patients with Active Axial Spondyloarthritis - ACR Meeting Abstracts
